We used to work together why college x essay However GSK is not giving up and in line with the Independent Data Monitoring Committee’s unanimous recommendation, it will continue the DERMA trial until the second co-primary endpoint is assessed. This endpoint, DFS in the gene signature positive sub-population, is designed to identify a subset of MAGE-A3 positive patients that may benefit from the treatment. Results from this analysis are expected in 2015.
Jordon
